Image-Based COVID Screening

About

Rapid Image-Based Screening for Bioactive Compounds that Block SARS-CoV-2 Replication Cycle Tech ID: UA20-225 Invention: This invention is a rapid image-based drug screening software platform for bioactive compounds that can block SARS-CoV-2 replication cycles. The invention utilizes a custom image processing algorithm that utilizes microscopy images to develop drug response profiles to identify lead compounds. This technology can also be used to neutralize antibodies, monobodies, or peptides. Background: Within the drug discovery process, lead compounds are chemical compounds that show desired biological or pharmacological activity and may initiate the development of a new clinically relevant compound. Lead compounds are commonly used as a starting point in drug design. With the advancement of technology, computer-aided drug design (CADD) has been incorporated into lead compound discovery within the drug discovery process. Since the severe acute respiratory syndrome SARS-CoV-2 (Coronavirus) has spread globally, there is a greater need to look for novel vaccines and drugs that alleviate and prevent contracting the virus. This includes identifying a possible lead bioactive compound that will block the coronavirus replication cycle to assist in the prevention and contamination of this current global pandemic.